# PROTOCOL: A randomized, double-blind, placebo-controlled, parallelgroup,
multicenter study to evaluate the safety and efficacy
of secukinumab 300 mg and 150 mg in adult patients with
active psoriatic arthritis after 16 weeks of treatment
compared to placebo and to assess the safety, tolerability
and efficacy up to 52 weeks

## Objectives
[To be defined]

## Design
